From the Journals

Menstrual irregularity appears to be predictor of early death


 

FROM THE BMJ

Expert suggests a probable underlying link

Dr. Reshef Tal

Dr. Reshef Tal

“Irregular menstrual cycles in women have long been known to be associated with significant morbidities, including the leading causes of mortality worldwide such as cardiovascular disease and cancer,” Reshef Tal, MD, PhD, assistant professor of obstetrics, gynecology & reproductive sciences at Yale University, New Haven, Conn., said in an interview. “The findings of this large study that irregular menstrual cycles are associated with premature death, most strongly from cardiovascular causes, are therefore not surprising.”

Dr. Tal acknowledged that one probable underlying link is PCOS, which is recognized as the most common hormonal disorder affecting women of reproductive age. The irregular periods that characterize PCOS are tied to a number of metabolic risk factors, including obesity, insulin resistance, dyslipidemia, and hypertension, which increase the long-term risk of cardiovascular disease and cancer of the uterus.

“The study did not have information on patients’ pelvic ultrasound findings and male hormone levels, which would have helped to establish PCOS diagnosis. However, women in this study who had irregular cycles tended to have more hirsutism, high cholesterol, hypertension as well as higher BMI, suggesting that PCOS is at least partly responsible for the observed association with cardiovascular disease. Interestingly, the association between irregular cycles and early mortality was independent of BMI, indicating that mechanisms other than metabolic factors may also play a role,” observed Dr. Tal, who was asked to comment on the study.

“Irregular periods are a symptom and not a disease, so it is important to identify underlying metabolic risk factors. Furthermore, physicians are advised to counsel patients experiencing menstrual irregularity, [to advise them to] maintain a healthy lifestyle and be alert to health changes,” Dr. Tal suggested.

The study was funded by the National Institutes of Health. The investigators had no relevant financial disclosures. Dr. Tal said he had no relevant financial disclosures.

SOURCE: Chavarro J et al. BMJ. 2020. doi: 10.1136/bmj.m3464.

Pages

Recommended Reading

Telemedicine meets menopause in customized patient care service
Clinician Reviews
Three-step approach may help relieve one of the itchiest vulvar conditions
Clinician Reviews
Consider switching up treatment regimens for recurrent bacterial vaginosis
Clinician Reviews
FDA updates info on postmarketing surveillance study of Essure
Clinician Reviews
New nonhormonal hot flash treatments on the way
Clinician Reviews
How ObGyns can best work with radiologists to optimize screening for patients with dense breasts
Clinician Reviews
Don’t discount ultrapotent topical corticosteroids for vulvar lichen sclerosus
Clinician Reviews
Fetal estrogens show promise for safer therapy for menopause
Clinician Reviews
Relugolix combo effective for uterine fibroids through 1 year
Clinician Reviews
PCOS tied to risk for cardiovascular disease after menopause
Clinician Reviews